ClinicalTrials.Veeva

Menu

An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status and phase

Completed
Phase 2

Conditions

Hepatitis C Infection

Treatments

Drug: BMS-790052
Drug: BMS-650032

Study type

Interventional

Funder types

Industry

Identifiers

NCT01051414
AI447-017

Details and patient eligibility

About

To assess the efficacy and safety profile of co-administration of BMS-790052 and BMS-650032 for 24 weeks treatment.

Enrollment

43 patients

Sex

All

Ages

20 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects chronically infected with HCV Genotype 1
  • HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening

Exclusion criteria

  • Subjects with evidence of liver cirrhosis
  • Evidence of HCC
  • Co-infection with hepatitis B virus, HIV

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

43 participants in 1 patient group

BMS-790052 + BMS-650032
Experimental group
Treatment:
Drug: BMS-790052
Drug: BMS-650032

Trial contacts and locations

4

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems